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Introduction
In the brain, the microtubule-associated protein tau promotes 
microtubule assembly and the axonal outgrowth of neurons; 
however, in certain diseases, tau becomes hyperphosphorylated, 
aggregates, and leads to neuronal death. Tau neuropathology is a 
hallmark of several neurodegenerative diseases known as tauop-
athies (1), including Alzheimer’s disease (AD). Although path-
ways underlying the development of tau neuropathology remain 
unclear, the role of polyamines in neurological disorders, includ-
ing AD (2, 3), has emerged. Polyamine imbalance may exacerbate 
disease progression by contributing to tau neuropathology and 
cognitive impairment.
Polyamines provide an assortment of physiological effects 
that provide neuronal function, axonal integrity, and cognitive 
processing (4–7). Under homeostatic conditions, the polyamine 
pathway remains highly self-regulating. Ornithine decarboxylase 
(ODC) remains the rate-limiting step in the biosynthesis of poly-
amines, as it is responsible for converting ornithine to putrescine 
and subsequent synthesis to spermidine and spermine. ODC 
activity, and more specifically translation, varies in response to 
cellular perturbation, most notably polyamine concentration (8). 
ODC degradation depends on a polyamine-activated antizyme 
(AZ, also referred to as an “antizyme for ODC”). AZ inhibits ODC 
with high affinity and prevents activity-dependent dimerization 
(9). Furthermore, AZ can be sequestered and inhibited by anti-
zyme inhibitors (AZINs) (See Figure 1A for simplified pathway), 
which associates with the positive regulation of ODC activity and 
polyamine biosynthesis.
Self-regulation of the pathway also occurs by polyamine retro- 
or back-conversion. Higher-order polyamines recycle back to their 
lower-order precursors via the catabolic enzymes spermine oxi-
dase (SMOX), spermidine/spermine-N1-acetyltransferase (SSAT), 
and polyamine oxidase (PAOX). The back-conversion produces 
acetylated metabolites of the polyamines, which either recycle 
to lower-order polyamines or persist as putatively inactive forms; 
however, the functional roles of acetylpolyamines remain unclear.
Increasing reports indicate that specific stimuli, either emo-
tional or physical, can elicit a polyamine stress response (PSR), 
resulting in altered central polyamine homeostasis (10). Although 
adaptive elevations in polyamines after a short-term stressor 
Tauopathies display a spectrum of phenotypes from cognitive to affective behavioral impairments; however, mechanisms 
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Figure 1. Polyamine transcripts increase in Alzheimer’s disease brain. (A) Simplified schematic of the polyamine pathway. Arginase 1 (ARG1), nitric 
oxide synthase (NOS), arginosuccinate synthetase (ASS1), arginosuccinate lyase (ASL), antizyme inhibitor 2 (AZIN2), ornithine decarboxylase anti-
zyme 1 (OAZ1), ornithine decarboxylase (ODC), spermidine/spermine N1-acetyltransferase 1 (SSAT), spermidine synthase (SRM), spermine synthase 
(SMS), spermine oxidase (SMOX), polyamine oxidase (PAOX). (B and C) Alzheimer’s disease brains show significantly dysregulated polyamine-as-
sociated gene transcripts. (B) Volcano plot displays statistical significance versus fold change on the y and x axes, respectively. Combining a P value 
statistical test with the fold regulation enables identification of transcripts with large and small expression changes that are statistically signifi-
cant. Fold regulation threshold = 1.5, P value threshold = 0.05. (C) Clustergram with nonsupervised hierarchical clustering of significantly dysregu-
lated gene transcripts to display a heat map with dendrograms indicating coregulated genes. Data was obtained using RT
2
 Profiler PCR array gene 
expression data analysis software from Qiagen.
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hippocampal tissue from AD brains compared 
with control brains (Figure 1, B and C, and Table 
1). Transcripts reflecting altered arginine metab-
olism included increased ASS1; ASL1, which 
promotes arginine synthesis and NOS2; and 
ARG1, which depletes arginine to produce nitric 
oxide and ornithine. Transcripts associated with 
polyamine signaling included increased prosyn-
thetic enzymes SMS and ODC1 and catabolic 
SAT1, SMOX, and PAOX enzymes, signifying 
dysregulation along the entire cycle of the poly-
amine axis. PMF1 also increased, which associ-
ates with increase SAT1 transcription together 
with NRF2 (16). Positive indirect regulators of 
polyamine production consisted of increased 
AZIN1, AZIN2, and AGMAT, whereas negative 
regulators consisted of OAZ1, OAZ3, OAT1, and 
OTC. Interestingly, AD brains showed elevated 
vesicular polyamine transporter SLC18B1 (17). 
Amongst the NMDA receptors, only the gluta-
mate ionotropic receptor NMDA type subunit 
2B (GRIN2B) increased. Most notably, of all the 
gene transcripts, the greatest change was AZIN2 
(fold change = 2.4341, P = 0.000048).
AZIN2 protein is increased in AD brains. We 
measured protein in the human postmortem 
AD brain for tau and AZIN2 levels to extend our 
transcriptome findings. Using a cluster analysis 
based on paired helical filament (PHF) phos-
pho-tau (AT8) in AD, we observed significant 
increases in high molecular weight (HMW) 
tau, phospho-tau (AT8, PHF1), and AZIN2 in 
AD brains that were positive for AT8 staining (AT8+; Figure 2, 
A–F). These data further support the correlation between tau 
neuropathology and dysregulation of polyamine metabolism 
regarding elevated AZIN2.
AZIN2 overexpression precipitates tau-dependent alterations 
in anxiety and cognition. To determine how chronic polyamine 
activation (sustained PSR) impacted affect and cognition during 
tau neuropathology, we overexpressed AZIN2 via adeno-associ-
ated viral constructs (AAV9-AZIN2) or an empty capsid plasmid 
in the cortex and hippocampus of nTg and tau PS19 mice (Fig-
ure 3A). Immunohistochemistry confirmed equal exogenous 
AZIN2 HA-tagged viral expression and AZIN2 in the cortex and 
hippocampus of nTg and PS19 mice, ensuring similar expression 
across groups (Figure 3, B and C). Although tau (HT7) remained 
unchanged after increased AZIN2 (Figure 3D), phospho-tau (AT8) 
increased in the cortex, hippocampus (CA3), and dentate gyrus 
(DG) in response to AZIN2 overexpression in PS19 mice (Figure 
3E). PS19 mice showed an increase in microglia activation in the 
hippocampus’s DG relative to nTg controls (Figure 3F) and inde-
pendent of AZIN2. These data suggest that chronic polyamine 
activation may facilitate tau neuropathology.
AZIN2 overexpression induced tau-dependent alterations in 
affective and cognitive processing (Figure 4, A–F). Overall, loco-
motor activity was comparable across all groups in terms of the 
total distance traveled (Figure 4A); however, AZIN2 overexpres-
might serve as beneficial, persistent stress and long-term PSR acti-
vation can become maladaptive, resulting in chronic polyamine 
dysregulation. Altered regulation in this pathway can occur at the 
level of the prosynthetic and catabolic enzymes, as well as their 
respective polyamine and acetylated products (2, 3, 11–15).
In the current study, we found that the gene transcript for 
AZIN2 was significantly altered in the AD brain compared with 
control brains. We confirmed increased AZIN2 protein in AD 
brains associated with phospho-tau. We also found that AZIN2 
overexpression promoted a maladaptive PSR in mice with under-
lying tau neuropathology, higher acetylpolyamines, and increased 
tau levels, and it precipitated cognitive and affective behavior-
al impairments. Importantly, nontransgenic (nTg) littermates 
behaviorally habituated to sustained polyamine activation. These 
data further cement the notion that the PSR differentially affects 
tauopathies. Increased polyamine metabolites may serve as medi-
ators of tau neuropathology and potential biomarkers associated 
with tau, including AD.
Results
AD brains indicate altered polyamine-associated gene transcripts. To 
determine how AD affects the polyamine pathway, we developed 
a focused PCR array platform harboring gene transcripts associat-
ed with arginine metabolism and polyamine signaling (Figure 1A). 
Polyamine transcripts were significantly changed in postmortem 
Table 1. Gene transcripts: Alzheimer’s disease versus control
Gene name Gene symbol Fold change P value
Antizyme inhibitor 2 AZIN2 2.43 0.0000
Spermine synthase SMS 2.24 0.0851
Nitric oxide synthase 2 NOS2 2.22 0.0032
Transient receptor potential cation channel subfamily V member 1 TRPV1 2.21 0.0026
Ornithine carbamoyltransferase OTC 2.15 0.0000
Ornithine decarboxylase antizyme 1 OAZ1 2.12 0.0051
Spermine oxidase SMOX 2.01 0.0007
Glutamate ionotropic receptor NMDA type subunit 2A GRIN2A 2.00 0.1099
Ornithine decarboxylase antizyme 3 OAZ3 1.89 0.0202
Argininosuccinate lyase ASL 1.87 0.0021
Toll-like receptor 2 TLR2 1.79 0.0959
Argininosuccinate synthase 1 ASS1 1.78 0.0000
Polyamine-modulated factor 1 PMF1 1.75 0.0025
Deoxyhypusine synthase DHPS 1.73 0.6620
Glutamate ionotropic receptor NMDA type subunit 1 GRIN1 1.70 0.0627
Ornithine decarboxylase 1 ODC1 1.67 0.0463
Glutamate ionotropic receptor NMDA type subunit 2B GRIN2B 1.67 0.0128
Arginase 1 ARG1 1.64 0.0053
TBC1 domain family member 25 TBC1D25 1.57 0.1039
Antizyme inhibitor 1 AZIN1 1.55 0.0305
Agmatinase AGMAT 1.49 0.0054
Ornithine aminotransferase OAT 1.48 0.0035
Peptidyl arginine deiminase 4 PADI4 1.41 0.0255
Solute carrier family 18 member B1 SLC18B1 1.40 0.0171
Spermidine/spermine N1-acetyltransferase 1 SAT1 1.35 0.0181
Polyamine oxidase PAOX 1.33 0.0081
Gene transcripts reflect Figure 1. P < 0.05 and fold change > 1.5.
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polyamine activation; however, underlying tauopathy promoted 
a unique maladaptive behavioral phenotype that impacted affect 
and cognitive performance in response to chronic PSR activation.
Existing tauopathy augments the PSR after chronic AZIN2 over-
expression. To determine how the polyamine system regulates 
itself in response to sustained polyamine activation by AZIN2 
overexpression and tau neuropathology, we quantified brain 
putrescine, spermidine, spermine, and acetylspermidine lev-
els (Figure 5, A–D). Overall, there was no change in spermidine 
sion increased anxiety in tau transgenic mice, as measured by 
decreased entries to the center zone and decreased time in the 
center zone (Figure 4, B and C). As determined by percentage of 
alternation in the Y maze, working memory declined in tau mice 
with chronic PSR activation (Figure 4D). Finally, inhibition and 
fear-associated memory recall, measured by latency to cross in 
the inhibitory avoidance task, was impaired in mice with tauopa-
thy and chronic AZIN2 overexpression (Figure 4, E and F). These 
data indicate that nTg littermates adapted behaviorally to chronic 
Figure 2. AZIN2 is increased in Alzheimer’s disease brains. (A) Images and quantification of Western blot analysis of human cortex for tau (Tau-5, AT8) 
and AZIN2. (B–F) A 1-way ANOVA revealed a group difference (control, AD positive for AT8 [AD/AT8+]) and AD negative for AT8 (AD/AT8–) on total tau (Tau-
5, 40–64 kDa), HMW total tau (Tau-5, 100–140 kDa), tau AT8, PHF1, and AZIN2 (P = 0.032; P = 0.001; P = 0.000; P = 0.000; P = 0.044, respectively). The 
(AD/AT8+) group showed increased Tau-5 relative to the (AD/AT8–) group (P = 0.029), an increase in HMW Tau-5 relative to the control group (P = 0.001) 
and the (AD/AT8–) group (P = 0.009), an increase in AT8 relative to the controls (P = 0.000) and the (AD/AT8–) group (P = 0.000), and an increase in PHF1 
relative to the control group (P = 0.000) and the (AD/AT8–) group (P = 0.000). AZIN2 increased in the (AD/AT8+) group relative to the control group (P = 
0.0366) and the (AD/AT8–) group (P = 0.0365). One-way ANOVA followed by post hoc comparisons using Tukey’s HSD, n = 5–9, data represented by scatter 
plot with bar. *P < 0.05; control versus (AD/AT8+); #P < 0.05; (AD/AT8+) versus (AD/AT8–).
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levels between groups, possibly because spermidine shows the 
highest abundance of all polyamines; however, putrescine and 
acetylspermidine significantly increased in response to AAV-AZ-
IN2 overexpression, and this response was augmented in PS19 
mice (Figure 5, A and D), indicating an interaction of polyamine 
activation and tau neuropathology through the induction of poly-
amine back-conversion.
At the protein level, exogenous AZIN2 was increased in 
response to AAV-AZIN2 overexpression, ensuring equal viral 
expression between nTg and PS19-treated mice (Figure 6, A and 
B), supporting the immunohistochemical distribution of AZIN2. A 
50-kDa band of AZIN2 also increased in response to AAV-AZIN2 
overexpression in PS19 mice (Figure 6C). Although this band would 
align with endogenous AZIN2, suggesting intrinsic activation, we 
cannot rule out a proteolytic product of exogenous AZIN2. Polyam-
ine pathway activation typically couples with catabolic enzymes to 
normalize polyamine levels; however, we found that in PS19 mice 
with AZIN2 overexpression, anabolic enzymes (i.e., ODC, SRM, 
SMS) increased, indicating a maladaptive PSR in tauopathies (Fig-
ure 6, D, F, and G). Overall, AZIN2 increased SSAT as a treatment; 
however, pairwise analysis indicated that the effect was driven 
in nTg mice (Figure 6H), suggesting that SSAT protein increased 
to normalize polyamines after chronic activation. This effect was 
reduced in PS19 mice, although acetylspermidine increased to a 
greater extent. This may suggest that acetylspermidine accumu-
lates more or is not cleared as readily during tauopathies and the 
PSR. Conversely, SMOX, which converts spermine to spermidine, 
decreased in PS19 mice with AZIN2 overexpression (Figure 6E), but 
was unchanged in nTg littermates, and supported the mean eleva-
tion in spermine in AZIN2-treated PS19 mice (Figure 5C). PAOX 
remained unchanged between groups (Figure 6I). These data sug-
gest that mice with tauopathy launched a unique PSR after chronic 
polyamine activation by AZIN2 overexpression, but that nTg mice 
functionally reestablished homeostasis of the polyamine pathway.
AZIN2 overexpression augments soluble, insoluble, and oligomer-
ic tau. Next, we examined whether chronic polyamine activation 
through AZIN2 overexpression affected tau neuropathology (Fig-
ure 7, A–K). Overexpression of AAV-AZIN2 appeared to precipitate 
monomeric and HMW soluble, insoluble, and oligomeric tau neu-
ropathology in PS19 mice. More specifically, AAV-AZIN2 overex-
pression increased soluble total tau (H150), AT8 (50–64 kDa), and 
phospho-epitopes pSer396 (HMW), pSer199/202 (HMW), and 
PHF1 (Figure 7, A–J). AZIN2 overexpression also increased insolu-
ble total tau (H150; 50–64 kDa), AT8 (50–64 kDa), and PHF1 (Fig-
ure 8, A–I). Lastly, AZIN2 overexpression increased oligomeric tau 
(T22; Figure 9, A–C). These data indicate that chronic polyamine 
activation through AZIN2 promoted soluble, insoluble, and oligo-
meric tau forms.
Spermine displaces tau from microtubules but facilitates tubu-
lin polymerization and bundling. To determine the relationship 
between polyamines, acetylpolyamines, microtubule polymeriza-
tion, and tau, we performed a tubulin polymerization assay (Figure 
10, A–F, and Table 2). Only spermine revealed a rapid increase in 
tubulin polymerization, namely during elongation (growth phase, 
Figure 10C); however, acetylspermine failed to promote tubulin 
polymerization (Figure 10F), suggesting differential effects of 
spermine versus acetylspermine on microtubule dynamics. To 
confirm these effects in cell culture, we treated stably transfected 
HeLa cells with tubulin-fused GFP construct with various sper-
mine concentrations. The mean average for tubulin bundling was 
elevated with 1 mM (not significant) as quantified by GFP fluo-
rescence (Figure 11, A and B). Finally, to understand the dynamic 
relationship between tubulin, tau, and polyamines, we performed 
a cosedimentation assay with HeLa cells that stably overexpressed 
4R0N human tau (C3H/tau). We found that although spermine 
increased tubulin polymerization, it did so at the expense of dis-
placing tau from microtubules (Figure 12, A–E). Accumulation of 
spermine reduced free tubulin (Figure 12C) and increased polym-
erized tubulin (Figure 12B). Conversely, increasing concentrations 
of spermine-displaced tau were associated with polymerized 
tubulin (heavy pellet) (Figure 12D) while increasing tau in the sol-
uble fraction (Figure 12E). These data signify that polyamines may 
acutely serve to stabilize neuronal integrity during a PSR; howev-
er, chronic elevation of higher-order polyamines may displace tau 
from microtubules, leading to cytoplasmic tau accumulation.
Polyamines and acetylpolyamines differentially affect tau fibril-
lization. To determine whether polyamines affected tau fibrilliza-
tion, we coincubated recombinant 4R0N WT tau with polyamines 
and acetylpolyamines in a solution using the thioflavin T assay 
(ThT assay) (Figure 13, A–F, and Table 3). Polyamines reduced tau 
fibrillization in a dose-dependent manner, as measured by AUC, 
and with higher-order polyamines (longer chain length) inhibiting 
fibrillization to a greater extent and with greater potency (Figure 
13, A–C). Both spermidine and spermine appeared capable of com-
pletely blocking tau fibrillization in this system as low as 10 μM, 
and importantly, this concentration exists well within the overall 
brain content of polyamines (18, 19). Strikingly, acetylpolyamines 
displayed a completely different profile for tau fibrillization. In 
general, acetylpolyamines failed to inhibit tau fibrillization, most 
notably in the lag and growth phase (Figure 13, D–F). Acetylsper-
midine, but to a greater extent acetylspermine, began to increase 
Figure 3. Overexpression of AZIN2 increased regional phosphorylated 
tau in the mouse CNS. (A–F) AZIN2 overexpression in a mouse model 
of tauopathy. (A) AAV9-AZIN2 viral construct, cortical and hippocampal 
injection sites, respective genotypes, and outcome measures used in the 
present study. (B) Cortical and hippocampal AAV9-AZIN2 expression by 
HA staining. The main effects analysis showed no interaction in the cortex 
(P = 0.172) or hippocampus (P = 0.604), ensuring equal expression. (C)
There was no effect of genotype on AZIN2 in the dentate gyrus (DG) (P = 
0.42), but a treatment effect on AZIN2 expression in the ACX, CA3, and 
DG (P = 0.000, P = 0.000, P = 0.000, respectively). (D) There was a main 
effect of genotype on tau (HT7) in the CTX, CA3, and DG (P = 0.001; P = 
0.000; P = 0.002, respectively). (E) There was a main effect of genotype 
on tau (AT8) in the CTX, CA3, and DG (P = 0.002; P = 0.000; P = 0.002, 
respectively); treatment in the CTX, CA3, and a trend toward a main effect 
in the DG (P = 0.036; P = 0.028; P = 0.057, respectively). Lastly, there was 
an interaction of genotype and treatment on AT8 in the CTX, CA3, and 
a trend toward an interaction in the DG (P = 0.040; P = 0.028; P = 0.058, 
respectively). Pairwise comparisons revealed AZIN2 overexpression 
increased AT8 in the CTX, CA3, and DG in PS19 mice (P = 0.001, P = 0.001, 
P = 0.003, respectively). (F) There was a main effect of genotype on IBA1 
in the DG (P = 0.022). A 2 × 2 factorial ANOVA was performed, followed 
by pairwise comparisons using Sidak’s posttest correction, n = 3–11, data 
represented by mean ± SEM. *P < 0.05. Scale bar: 500 μm for panel B; ×20 
original magnification (6% zoom). Scale bar: 50 μm for panels C–F; ×20 
original magnification (15% zoom = images; 60% zoom = insets).
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tau fibrillization, suggesting that even low (10 μM) concentrations 
of higher-order acetylpolyamines may promote tau fibrillization 
(Figure 13, E and F).
Spermine prevents higher-order aggregation of tau in C3H/tau 
cells. To further understand polyamines and tau interaction, we 
used C3H/tau cells with increasing concentrations of putrescine, 
spermidine, and spermine for 72 hours (Figure 14, A–M). Sper-
mine emerged as having the greatest effect 
on tau biology, namely in the accumulation 
of pSer396 and total tau (H150), which is 
associated with a significant increase in 
SSAT expression (Figure 14, C and E–G). 
Further, spermine significantly decreased 
soluble HMW total tau (H150; Figure 14, H 
and I) and insoluble HMW, oligomeric, and 
monomeric total tau (H150; Figure 14, J–M), 
indicating that spermine prevented tau from 
accumulating into HMW species and seques-
tered tau in a monomeric state.
To understand the temporal profile, 
C3H/tau cells were treated with spermine 
for 24 hours to understand the impact on tau 
biology and SSAT. Under these conditions, 
the induction of SSAT appeared to occur 
within 24 hours, as spermine increased SSAT 
expression (Figure 14, N and O) but did not 
significantly accumulate monomeric tau at 
24 hours in cells (Figure 14, N and O).
Polyamines and acetylpolyamines dif-
ferentially affect tau oligomerization. To 
determine whether acetylpolyamines could 
promote disease progression, we created a 
stable monoclonal split superfolded GFP-
Tau cell line using murine neuroblastoma 
Neuro-2a cells (aka N2a-ssGT) to measure 
tau oligomerization by complementation 
of 2 split GFP proteins. Validation of indi-
vidual plasmids and the stable monoclonal 
N2a-ssGT cell line was performed (Fig-
ure 15, A–C). Cotransfection of both plasmids, GFP10C (1–212 
aa)-Tau and GFP11C (213–228 aa)-Tau, in naive N2a cells suc-
cessfully caused GFP protein complementation and fluoresced 
green (Figure 15A). Subsequently, we continually selected for a 
monoclonal N2a-ssGT cell line to stably express the 2 split GFP-
Tau proteins. By coupling the BioTek Cytation 3 Cell Imaging 
Multi-Mode Reader and Accuri C6 flow cytometer, we were able 
Figure 4. Sustained AZIN2 impacts behavior in tau transgenic mice. (A–F) AZIN2 overexpression pre-
cipitates tau-dependent alterations in anxiety and cognition. (A–C) There were no effects of genotype, 
treatment, or interaction on total distance traveled in the open field; however, a significant interaction 
was found on the number of entries to the center zone (P = 0.023) and time in the center zone (P = 
0.044), indicating AAV9-AZIN2–precipitated tau-dependent alterations in anxiety. (D) There was no 
effect of genotype, treatment, or interaction on Y-maze percentage alternation; however, pairwise com-
parisons revealed a reduction in percentage alternation in PS19 mice (P = 0.046), an effect absent in nTg 
mice, indicating that AAV9-AZIN2 precipitated a tau-dependent impairment in working memory. (E and 
F) There was no effect of genotype on latency to cross on day 1 or day 2; however, there was a main effect 
of treatment on latency to cross on day 1 and day 2 (P = 0.023; P = 0.002, respectively). Pairwise compar-
isons revealed that latency was increased on day 1 and decreased on day 2 in PS19 mice (P = 0.034; P = 
0.001, respectively), indicating that AAV9-AZIN2 affected tau-dependent basal inhibition and impaired 
tau-dependent fear-associated memory recall. These effects were not observed in nTg mice. A 2 × 2 
factorial ANOVA was performed, followed by pairwise comparisons using Sidak’s posttest correction, n = 
6–12, data represented by mean ± SEM; *P < 0.05.
Figure 5. AZIN2 overexpression induces polyamine and acetylpolyamine accumulation. (A) There was an effect of genotype (P = 0.023) and treatment (P = 
0.000) on putrescine; however, pairwise comparisons revealed that while AAV9-AZIN2 increased putrescine in nTg (P = 0.000) and PS19 mice (P = 0.000), there 
was also a significant difference between nTg AAV9-AZIN2–treated mice and PS19 AAV9-AZIN2–treated mice (P = 0.028), indicating an interaction between tau 
and AAV9-AZIN2–induced putrescine. (B) There was no effect of genotype, treatment, or interaction on spermidine. (C) There was no effect of genotype, treat-
ment, or interaction on spermine; however, pairwise comparisons revealed a trend toward increased spermine in AAV9-AZIN2–treated PS19 mice (P = 0.060). 
(D) There was an effect of genotype (P = 0.040) and an effect of treatment (P = 0.000) on acetylspermidine; however, pairwise comparisons revealed that while 
AAV9-AZIN2 increased acetylspermidine in nTg (P = 0.024) and PS19 mice (P = 0.000), there was also a significant difference between nTg AAV9-AZIN2–treated 
mice and PS19 AAV9-AZIN2–treated mice (P = 0.019), indicating an interaction between tau and AAV9-AZIN2–induced acetylspermidine. A 2 × 2 factorial ANO-
VA was performed, followed by pairwise comparisons using Sidak’s posttest correction, n = 5–8, data represented by mean ± SEM; *P < 0.05.
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fluorescence using flow cytometry. In this model, spermidine 
ameliorated tau aggregation (Figure 16, C and D) and seeding, 
whereas acetylspermidine and acetylspermine exacerbated tau 
aggregation and seeding (Figure 16, C–F), again highlighting the 
bidirectionality of polyamines and their acetylated byproducts on 
disease continuance.
Discussion
Reports show that AZIN2 protein expression occurs along the 
axons of AD brains. Its expression pattern appears vesicle-like 
distributed in the somas of selected cortical pyramidal neurons 
and colocalized with NMDA receptors (20). Although polyamine 
dysregulation occurs in tauopathies (2, 3, 21–23), its direct rela-
tionship with tau neuropathology is less clear (24). Herein, we 
confirmed polyamine dysregulation in AD brains and showed that 
chronic AAV-AZIN2 overexpression increased tau neuropathology 
in PS19 mice, suggesting that AZIN2 might contribute to disease 
progression. Polyamines may serve multiple roles depending on 
the beginning, progression, and end stages of the disease. Recent 
reports suggest that even peripheral polyamine dysregulation 
is detectible in AD and can be used to predict patients with mild 
cognitive impairment converting to AD up to 2 years earlier than 
conventional clinical diagnosis (21). These data suggest polyam-
to demonstrate both GFP fluorescence images (Figure 15B) and 
GFP percentage (44.7%, Figure 13C) in N2a-ssGT cells.
N2a-ssGT cells were incubated with polyamines or acetyl-
polyamines for 72 hours and tau oligomerization was measured 
by GFP fluorescence and percentage. Spermidine and spermine 
decreased oligomerization (Figure 15, D and G–J), and acetyl-
putrescine and acetylspermine increased tau oligomerization 
(Figure 15, D–F, I, and J). Although it is difficult to predict the 
various endogenous concentrations of polyamines and acetyl-
polyamines within this cell line and their impacts on tau biolo-
gy, these data signify a beneficial role for the accumulation of 
at least some polyamines in reducing tau oligomerization and a 
detrimental role for the accumulation of acetylated products on 
tau oligomerization.
Polyamines and acetylpolyamines differentially affect tau aggre-
gation and seeding. Next, using Tau RD P301S FRET biosensor 
cells (ATCC, CRL-3275) and human recombinant tau441 (2N4R) 
P301S mutant preformed fibrils (Tau [P301S] PFFs), we deter-
mined how polyamines and acetylpolyamines affect tau aggrega-
tion and seeding (Figure 15, A and B). After a 48-hour incubation, 
FRET cells were treated with 30, 100, or 300 μM spermidine, 
acetylspermidine, spermine, or acetylspermine and 10 nM Tau 
(P301S) PFFs and were imaged and quantified for percentage 
Figure 6. AZIN2 overexpression induces tau-dependent effects on polyamine enzymes. (A) Representative Western blot images of hippocampal 
polyamine enzyme dysregulation. (B) There was an effect of treatment (P = 0.000) on exogenous AZIN2 levels (55 kDa) but no difference between nTg 
AAV9-AZIN2–treated and PS19 AAV9-AZIN2–treated mice (P = 0.682), indicating equal viral expression across groups. (C) There was an effect of genotype 
(P = 0.012), a trend toward an effect of treatment (P = 0.068), and a significant interaction (P = 0.045) on endogenous AZIN2 levels (50 kDa). (D) There 
was an effect of treatment (P = 0.022) on SMS. Pairwise comparisons revealed AAV9-AZIN2 increased SMS in PS19 mice (P = 0.017). (E) There was an 
effect of genotype (P = 0.012), treatment (P = 0.003), and an interaction (P = 0.030) on SMOX. (F) There was an effect of genotype (P = 0.001), treatment 
(P = 0.009), and interaction of genotype and treatment (P = 0.036) on ODC. Pairwise comparisons revealed AAV9-AZIN2 increased ODC in PS19 mice (P = 
0.002). (G) There was an effect of genotype (P = 0.027) and treatment (P = 0.009) on SRM. Pairwise comparisons revealed AAV9-AZIN2 increased SRM in 
PS19 mice (P = 0.004). (H) There was an effect of treatment (P = 0.014) on SSAT. Pairwise comparisons revealed AAV9-AZIN2 increased SSAT in nTg mice 
(P = 0.031). (I) No effect of genotype, treatment, or interaction of genotype and treatment detected on PAOX. A 2 × 2 factorial ANOVA was performed, 
followed by pairwise comparisons using Sidak’s posttest correction, n = 5–6, data represented by mean ± SEM; *P < 0.05.
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Figure 7. AZIN2 overexpression increases soluble tau species. (A) Representative Western blot images of hippocampal soluble tau. (B) There was 
an effect of genotype (P = 0.000), treatment (P = 0.008), and an interaction (P = 0.017) on total tau H150 (50 kDa). (C) Pairwise comparisons revealed 
AAV9-AZIN2 increased tau H150 (50 kDa) in PS19 mice (P = 0.001). There was an effect of genotype (P = 0.000), treatment (P = 0.004), and an interac-
tion (P = 0.008) on HMW H150 (>140 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased HMW tau H150 in PS19 mice (P = 0.000). (D) There was 
an effect of genotype (P = 0.004) on AT8 (50–64 kDa). Pairwise comparisons revealed AAV9-AZIN2 increase AT8 in PS19 mice (P = 0.032). (E) There was 
an effect of genotype (P = 0.000) on HMW AT8. (F) There was an effect of genotype (P = 0.000) on pSer396 (50–64 kDa) and HMW pSer396 (P = 0.006). 
(G) Pairwise comparisons revealed AAV9-AZIN2 increased HMW pSer396 in PS19 mice (P = 0.003). (H) There was an effect of genotype (P = 0.000) on 
pSer199/202 (50–64 kDa). (I) There was an effect of genotype (P = 0.000), treatment (P = 0.012), and an interaction (P =0.038) on HMW pSer199/202. (J) 
There was an effect of genotype (P =0.002) on monomeric PHF1 (50 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased monomeric PHF1 in PS19 
mice (P = 0.011). (K) There was an effect of genotype (P = 0.043) on HMW PHF1 (140–250 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased 
HMW PHF1 in PS19 mice (P = 0.048). A 2 × 2 factorial ANOVA was performed, followed by pairwise comparisons using Sidak’s posttest correction, n = 6, 
data represented by mean ± SEM; *P < 0.05.
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studies. For example, the increased latency to cross on training day 
1 of inhibitory avoidance testing would typically indicate increased 
basal inhibition and presumably increase latency on day 2; how-
ever, this was not the case. We observed a decreased latency to 
ine system dysfunction and acetylated byproducts as potential 
biomarkers for tauopathies, including AD.
Behaviorally, a unique interaction between polyamine activa-
tion, tau pathology, affect, and cognition emerged during these 
Figure 8. AZIN2 overexpression increases insoluble tau species. (A) Representative Western blot images of hippocampal insoluble tau. (B) There was an 
effect of genotype (P = 0.000) and an interaction (P = 0.014) with insoluble total tau (H150) (50–64 kDa). (C) There was an effect of genotype (P = 0.000) on 
insoluble HMW tau H150. (D) There was an effect of genotype (P = 0.026) on insoluble AT8 (50–64 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased 
insoluble AT8 (50–64 kDa) in PS19 mice (P = 0.011). (E) There was an effect of genotype (P = 0.001) on insoluble HMW AT8. (F) There was an effect of genotype 
(P = 0.000) on insoluble pSer396 (50–64 kDa). (G) There was an effect of genotype (P = 0.001) on insoluble HMW pSer396. (H) There was an effect of genotype 
(P = 0.002), treatment (P = 0.043), and an interaction (P = 0.020) with insoluble PHF1 (50–64 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased 
PHF1 (50–64 kDa) in PS19 mice (P = 0.003). (I) There was an effect of genotype (P = 0.000), treatment (P = 0.025), and an interaction (P = 0.025) with insoluble 
HMW PHF1 (140–250 kDa). Pairwise comparisons revealed AAV9-AZIN2 increased PHF1 (50–64 kDa) in PS19 mice (P = 0.003). A 2 × 2 factorial ANOVA was 
performed, followed by pairwise comparisons using Sidak’s posttest correction, n = 6, data represented by mean ± SEM; *P < 0.05.
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ments in contextual fear conditioning as early as 7.5 months (31). 
However, we did not detect behavioral impairments in 8-month-
old PS19 mice treated with AAV9–empty capsid compared with 
nTg mice treated with AAV9–empty capsid. The phenotypic drift 
of up to 6 months has been described in PS19 mice and variability 
in onset and severity of tau pathology (32), which may explain why 
no significant cognitive impairments were detected in the PS19 
AAV9–empty capsid mice. Nonetheless, the lack of behavioral 
impairment despite underlying tau pathology at this age might 
mirror cognitive reserve or resilience as seen in some patients, and 
activation of the PSR during this window precipitated additional 
tau phenotypes; however, additional research remains necessary 
in other models of tauopathy.
cross on day 2, indicating impaired fear-associated memory recall 
in PS19 AAV9-AZIN2–treated mice. Although there are numer-
ous reports exploring polyamines and cognitive processing (25), 
effective regulation (26), and suicidality (27–29), additional mea-
sures of AZIN2 overexpression and/or polyamine dysregulation 
on affective processing should be further explored, particularly in 
the context of dementias. More clearly, we observed the precipita-
tion of anxiety-related behavior, as seen in the open-field task, and 
impairment in working memory, as seen in the Y maze, identify-
ing what we believe is a unique impact of tauopathy in response to 
chronic PSR activation on cognitive and affective processing.
PS19 mice show impairments in spatial learning and memory 
in the Morris water maze as early as 6 months (30) and impair-
Figure 9. AZIN2 overexpression precipitates oligomeric tau neuropathology. (A) Representative dot blot images of hippocampal oligomeric tau neu-
ropathology. (B) There was an effect of genotype (P = 0.000), a trend toward an effect of treatment (P = 0.054), and an interaction (P = 0.049). Pairwise 
comparisons revealed AAV9-AZIN2 increased T22 oligomeric tau in PS19 mice (P = 0.008). A 2 × 2 factorial ANOVA was performed, followed by pairwise 
comparisons using Sidak’s posttest correction, n = 6–8, data represented by mean ± SEM; *P < 0.05.
Figure 10. Polyamines and acetylpolyamines differentially affect tubulin polymerization. (A–F) Tubulin polymerization assay and treatment of polyam-
ines (putrescine, A; spermidine, B; spermine, C) or acetylpolyamines (acetylputrescine, D; acetylspermidine, E; acetylspermine, F), followed by quantifica-
tion of the AUC compared with vehicle controls. Data represented as triplicate averages, and Table 2 reflects AUC change from vehicle control.
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seeding/propagation by different methods, whereas acetylsper-
midine showed reduced or opposite effects. Importantly, spermi-
dine (the median polyamine) showed the greatest abundance of all 
the polyamines in the brain and possibly offers substrate for both 
putrescine and spermine when needed. Although spermidine did 
not affect tubulin polymerization, spermine showed a different 
profile due to the longer aliphatic chain length and strength of its 
positive charges. Spermine also reduced tau fibrillization/oligom-
erization but to a lesser extent affected tau seeding/propagation. 
However, acetylspermine increased tau fibrilization/oligomeriza-
tion and promoted tau seeding/propagation.
Spermine also increased tubulin polymerization and bundling 
but did so at the expense of displacing tau from microtubules. These 
data are not surprising given that the binding sites of spermine to 
tubulin (aa residues 430–432 and 444–451) overlap with that of tau 
and tubulin (aa residues 421–441), providing a possible mechanism 
by which tau displacement from tubulin could result from increased 
levels of spermine (34). Additionally, in regard to tubulin binding, 
spermine and tau binding sites overlap with calcium binding (aa 
residues 421–443), which is also altered in patients with AD and 
mouse models of AD (35). In our studies, spermine sequestered 
tau in a soluble monomeric state, preventing the accumulation of 
soluble and insoluble HMW tau species in C3H/tau cells. Addi-
tionally, spermine decreased insoluble monomeric tau in C3H/tau 
cells and prevented tau dimerization/oligomerization in N2a-ssGT 
cells. Altogether, it remains tempting to speculate that during acute 
stress, the PSR becomes activated to promote transient polyam-
ine accumulation for neuronal support coupled with end-product 
removal (acetylpolyamines) after the resolution of stress. Howev-
er, an alternative outcome suggests that displaced tau is also left 
vulnerable for fibrillization/oligomerization by the accompanying 
increase in acetylpolyamines due to SSAT induction. Increased 
spermidine and spermine were capable of inducing SSAT over time. 
Ultimately, the effects of acetylpolyamines on tau aggregation with-
in the cell depend on the cell’s ability to clear acetylated products. 
Given that acetylpolyamines affect tau in different capacities (i.e., 
oligomerization/fibrillization/seeding), efflux of acetylpolyamines 
(extracellular accumulation) could also render further tau seeding/
Polyamine levels change over time in the brains of PS19 mice 
(33). To further our understanding of how polyamine dysregu-
lation aids in developing tau neuropathology, we tested several 
mechanisms at the molecular level involving polyamines versus 
acetylpolyamines, tau aggregation, and tubulin interaction. Our 
findings identified spermidine and spermine having the greatest 
effects on tau biology, whereas their acetylated products showed 
null or opposite tau effects, implicating SSAT as a potential media-
tor. Spermidine reduced tau fibrillization, oligomerization, and tau 
Table 2. Tubulin polymerization
Putrescine % Vehicle % Change
Control
0.3 mM 96 –4
1 mM 92 –8
Spermidine % Vehicle % Change
Control
0.3 mM 96 –4
1 mM 99 –1
Spermine % Vehicle % Change
Control
0.3 mM 116 16
1 mM 108 8
Acetylputrescine % Vehicle % Change
Control
0.3 mM 94 –6
1 mM 89 –11
Acetylspermidine % Vehicle % Change
Control
0.3 mM 92 –8
1 mM 93 –7
Acetylspermine % Vehicle % Change
Control
0.3 mM 91 –9
1 mM 108 8
 
Figure 11. Spermine affects tubulin bundling. (A and B) A 1-way ANOVA indicated no significant effect of treatment on tubulin bundling; however, post hoc 
analyses showed 1 mM spermine trended toward tubulin bundling (P = 0.087) relative to control. One-way ANOVA followed by post hoc analyses using Dunnett’s 
2-sided correction, n = 7–12, data were represented by box-and-whisker plot displaying the minimum, first quartile, median, third quartile, and maximum.
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status through PSR activation may seed tauopathies and vice versa. 
We recognized that although AZIN2 was the primary focus in these 
studies, many of the polyamine transcripts in the AD brain changed. 
Importantly, this system is typically self-correcting and tightly reg-
ulated. In our animal studies, the presence of tau altered polyamine 
homeostasis and instead promoted a feed-forward loop by chron-
ically increasing many anabolic enzymes along the entire axis. Fur-
ther, while polyamines may possess acute stabilizing effects on neu-
ronal function through microtubule homeostasis and prevention 
of tau fibrillization, the long-term polyamine flux (i.e., recurrence 
and magnitude) may also contribute to disease progression through 
propagation and tau spreading. Although it remains difficult to iso-
late the exact compartmental concentrations of polyamines versus 
acetylpolyamines within and outside cells, particularly because of 
rapid interconversion between various polyamine pools, we demon-
strated that targeted disruption of SSAT prevented the accumula-
tion of acetylated byproducts and reduced tau neuropathology (24).
In conclusion, our findings cemented the notion of polyamine 
dysregulation in AD brains and demonstrated that altered poly-
amine dysregulation, through increased AZIN2, precipitated tau 
neuropathology and induced cognitive and affective impairments. 
These data also suggest the intriguing notion that altered polyamine 
Figure 12. Spermine increases tubulin polymerization and displaces tau. (A) Representative Western blot images of insoluble and soluble fractions of 
tubulin and tau from a cosedimentation assay. (B–E) A 1-way ANOVA indicated a significant effect of treatment on soluble tubulin, insoluble and soluble 
tau from spermine treatment (P = 0.000, P = 0.039, P = 0.022, respectively). Post hoc analyses indicated that 0.5 mM, 1 mM, and 3 mM decreased soluble 
tubulin (free soluble) (P = 0.042, P = 0.001, P = 0.000, respectively); 1 mM and 3 mM decreased insoluble tau (heavy pellet) (P = 0.033, P = 0.032, respec-
tively); 1 mM and 3 mM increased soluble tau (free soluble) (P = 0.014, P = 0.016, respectively) relative to control. One-way ANOVA followed by post hoc 
comparisons using Dunnett’s 2-sided correction, n = 3 (2 independent experiments), *P < 0.05, data represented by mean ± SEM.
Figure 13. Polyamines and acetylpolyamines differentially affect tau fibrillization. (A–F) Thioflavin T (ThT) assay using recombinant 4R0N WT tau and 
treatment of polyamines (putrescine, A; spermidine, B; spermine, C) or acetylpolyamines [acetylputrescine], D; acetylspermidine, E; acetylspermine, F), 
followed by quantification of the AUC compared with Tau + Vehicle controls. Data are represented as triplicate averages and Table 3 reflects AUC change 
from vehicle control (%Tau + Vehicle, %Change).
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lines. Brain (cortex) from cases of neuropathologically confirmed AD (n 
= 15; age range 67–100; [81.8 ± 1.8, mean ± SEM]) and normal cases (n = 
10; age range 69–89; [78.5 ± 2.4, mean ± SEM]) were obtained. The aver-
age PMI was (AD = 14.9 ± 2.1, mean ± SEM; C = 16.1 ± 2.2, mean ± SEM). 
Samples were categorized for sex, Braak Staging, and phospho-tau posi-
tivity (tau AT8 positive or negative, Supplemental Tables 4–6).
qRT-PCR. The cDNA from human samples, used with RT2 SYBR 
Green qPCR Mastermix (Qiagen, 330529), was performed using a cus-
tom RT2 Profiler PCR array (Qiagen, 330171), according to the manu-
facturer’s protocol. CT values exported to an Excel file were uploaded to 
the analysis web portal at http://www.qiagen.com/geneglobe. Samples 
were assigned to controls or test groups. CT values were normalized 
based on a manual selection of reference genes. The data analysis web 
portal calculates the fold change/regulation using the ΔΔCT method, in 
which ΔCT is calculated between the gene of interest and an average 
of housekeeping genes, followed by ΔΔCT calculations (ΔCT [experi-
ment] – ΔCT [control]). Fold-change was calculated using the 2–ΔΔCT 
formula. The data analysis web portal generated a scatter plot, heat-
map, hierarchy clustergram analysis, and multigroup plot data analy-
sis. Each 96-well plate contained 43 disease-focused transcripts and 2 
housekeeping genes per sample (1 control and 1 AD sample per plate). 
In addition, 1 well contained a genomic DNA control, 1 well contained 
reverse-transcription controls, and 1 well contained positive PCR con-
trols per sample, all of which passed quality control metrics. In this 
study, we report a total of 47 genes profiled on 18 samples.
Mice. All animal procedures were performed following the IACUC 
at the University of South Florida Health Byrd Alzheimer’s Institute. 
Male and female nTg (C57BL/6J, 000664) and tau PS19 transgen-
ic mice [Tg(Prnp-MAPT*P301S)PS19Vle, The Jackson Laboratory, 
008169] were used, and experimental group assignments were bal-
anced for genotype, gender, and litter (37).
Viral production. AZIN2 was cloned into the rAAV vector pTR2-
MCS. This vector expressed the AZIN2 with the chicken β-actin CMV 
hybrid promoter and contained the AAV2 terminal repeats. The AZIN2 
was also appended on the N-terminus with an HA tag to detect the 
expressed protein. rAAV serotype9 viral particles were generated from 
a triple transfection into HEK293 cells (ATCC, CRL-1573), followed by 
purification as described previously (38).
Surgical procedures. At 4 months of age, nTg and tau PS19 mice 
were anesthetized with isoflurane, and a volume of 2 μL of AAV 
particles containing AVV9–empty capsid (EC) or AZIN2 (3 × 1012 
vg/mL) were stereotaxically injected bilaterally into the CA3 of 
the hippocampus and the anterior cortex. Stereotaxic coordinates 
from bregma were AP = –2.5 mm, ML = ±2.9 mm, and DV = –3.0 mm 
for the hippocampus, and AP = 2.2 mm, ML = ±1.7 mm, and DV = 
–3.0 mm for the cortex. The virus was administered using convec-
tion-enhanced delivery at a constant rate of 1.5 μL/min (39). Viral 
incubation was 4 months at the start of behavioral testing and was 5 
months at the time of euthanasia and tissue collection.
Behavioral testing. Four months after viral incubation, mice 
began behavioral tasks to assess alterations in affective processing, 
cognitive performance, and motor performance. Behavioral tasks 
were run in sequence to minimize stress effects on behavioral per-
formance and were adequately spaced out over a month to prevent 
carryover effects on performance. White noise (55 dB) was present 
during all testing. The experimenter was blinded to the sample 
group allocation during data collection.
indirect mechanisms, such as tau displacement and accumulation 
of acetylated byproducts to facilitate disease progression. These 
data highlight a potentially novel interaction between tau neuro-
pathology, polyamine regulation, and behavioral impairments and 
suggests potentially new therapeutic strategies along the polyamine 
axis to treat tauopathies, including AD.
Methods
Human hippocampal brain tissue. For qRT-PCR analyses, the Institute 
for Brain Aging and Dementia Tissue Repository at the University of 
California (Irvine) provided human postmortem hippocampal tissue 
from AD and control patients. Pathological and clinical criteria con-
firmed the diagnosis of AD. Tissue was frozen at autopsy and stored 
at –80°C until use. Control and AD samples were matched for age and 
gender. RNA was extracted as previously described (36) and was ana-
lyzed by qRT-PCR. Eight total control samples (2 male, 6 female) and 
10 AD samples (4 male, 6 female) were analyzed for gene transcripts. 
To accurately match for age/gender across PCR-array plates (which 
included 1 control and 1 AD sample), 2 male control samples were used 
twice; however, their re-run data was not included in analyses. A table 
depicting the distribution of age, gender, and postmortem interval 
(PMI) of qRT-PCR samples can be found in Supplemental Tables 1–3.
For Western blot analyses, samples were deidentified and obtained 
from the NIH NeuroBioBank following the institutional bioethics guide-
Table 3. Thioflavin T assay tau aggregation
Putrescine % Tau + Vehicle % Change
Tau + Vehicle 100
300 μM 89 –11
1 mM 45 –55
Spermidine % Tau + Vehicle % Change
Tau + Vehicle 100
10 μM 64 –36
30 μM 58 –42
100 μM 32 –68
Acetylputrescine % Tau + Vehicle % Change
Tau + Vehicle 100
100 μM 90 –10
300 μM 87 –13
1 mM 92 –8
Acetylspermidine % Tau + Vehicle % Change
Tau + Vehicle 100
10 μM 111 11
30 μM 112 12
100 μM 105 5
Spermine % Tau + Vehicle % Change
Tau + Vehicle 100
10 μM 57 –43
30 μM 10 –90
100 μM 3 –97
Acetylspermine % Tau + Vehicle % Change
Tau + Vehicle 100
10 μM 200 100
30 μM 142 42
100 μM 67 –33
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Y maze. The Y maze was used to assess working memory. Animals 
were allowed to freely explore the maze for 5 minutes while being 
monitored by video tracking software. Maze measurements were as 
follows: 35 cm × 5 cm × 10 cm (L × W × H). Alternation was calculat-
ed as the percentage of successful alternations (entering each arm at 
least once in 3 attempts) of total possible alternations (number of arm 
entries minus 2). Animals performing a decreased number of alterna-
tions is indicative of impaired working memory.
Open field. The open-field test was used to assess general locomotor 
and anxiety-like behavior. Animals were allowed to freely explore the 
maze for 15 minutes in a 44 cm2 open field while being monitored by vid-
eo tracking software (AnyMaze software; Stoelting Company). Activity 
levels were evaluated by total distance traveled. Anxiety was assessed by 
the number of entries to the center zone and time spent in the appara-
tus’s center zone. Animals that show a decreased tendency to explore in 
the center of the field can be indicative of a higher anxiety level.
Figure 14. Spermine sequesters tau in monomeric state, preventing higher-order aggregation, in tau-overexpressing cells. (A–C) Representative 
Western blot images of C3H/tau cells; 72 hours. (D–G) Spermidine (0.05–0.1 mM) decreased pS199/202 (P = 0.036, P = 0.043, respectively), and 
(0.05–0.5 mM) increased SSAT (P = 0.000, P = 0.001, P =.001, P = 0.000, respectively). Spermine (0.5 mM) increased tau pS396 (P = 0.023), tau H150 
(P = 0.019), and (0.05, 0.1, 0.25, and 0.5 mM) SSAT (P = 0.033, P = 0.018, P = 0.012, and P = 0.028, respectively). (H and I) Representative West-
ern blot images of C3H/tau cells. (J) Spermine (0.5 mM) reduced soluble total tau (H150; P = 0.001). (K) Spermine (0.1, 0.25, 0.5, 1.0 mM) reduced 
insoluble HMW (>200 kDa) total tau (H150; P = 0.0186, P = 0.002, P = 0.000, P = 0.000, respectively). (L) Spermine (0.5–1.0 mM) reduced insoluble 
oligomeric (140–170 kDa) total tau (H150; P = 0.002, P = 0.001, respectively). (M) Spermine (0.5–1.0 mM) reduced insoluble tau (55 kDa) (H150; P = 
0.025, P = 0.002, respectively). (N) Representative Western blot images of C3H/tau cells. (O) Spermine (0.5 mM) trended toward increased SSAT 
expression (P = 0.087). One-way ANOVA followed by Dunnett’s 2-sided correction, n = 3 triplicates (3 independent experiments), *P < 0.05, data 
represented by mean ± SEM.
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by a partition with a sliding door. On day 1, the animal was placed 
into the brightly lit side of the chamber; after 30 seconds the door 
opened to the dark chamber and upon entering the dark chamber, 
the mice received a mild foot shock (0.5 mA, 1 second). On day 2, 
the animals were placed in the brightly lit chamber and after 30 
Inhibitory avoidance. The inhibitory avoidance test was used to 
assess inhibition and fear-associated recall based on the associa-
tion between a specific environmental context, which the animal 
learns to avoid, and an aversive stimulus represented by a mild 
foot shock. The testing apparatus was divided into 2 compartments 
Figure 15. Polyamines decrease tau oligomerization while acetylpolyamines increase tau oligomerization. (A–C) Validation of split GFP-Tau plasmids 
(pmGFP10C-Tau, pmGFP11C-Tau) and a monoclonal cell line (N2a-ssGT). (D) Representative images of tau oligomerization after treatment with polyamines/
acetylpolyamines for 72 hours. Original magnification, ×10. (E–J) Graphs and histograms show the effect of treatment on tau oligomerization, as measured 
by percentage GFP (P =0.000). Spermidine and spermine (30 μM) decreased tau oligomerization compared with controls (P = 0.003, P = 0.002, respective-
ly), while acetylputrescine and acetylspermine increased tau oligomerization (P = 0.007, P = 0.007, respectively) compared with controls. PTS: putrescine, 
Ac-PTS: acetylputrescine, SPD: spermidine, Ac-SPD: acetylspermidine, SPM: spermine, Ac-SPM: acetylspermine. Acetylputrescine (30 μM) trended toward 
increased tau oligomerization (P = 0.062) compared with 30 μM putrescine. Acetylspermidine (30 μM) increased tau oligomerization (P = 0.008) compared 
with 30 μM spermidine. Acetylspermine (30 μM) increased tau oligomerization (P = 0.000) compared with 30 μM spermine. One-way ANOVA followed by 
post hoc comparisons using Tukey’s HSD, n = 6–8, *P < 0.05; data represented by mean ± SEM.
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tected by sequential immersion in 10%, 20%, and 30% sucrose solu-
tions for 24 hours each. Brains were sectioned at 25 μm using a sliding 
microtome and stored at 4°C in Dulbecco’s PBS containing 100 mM 
sodium azide until staining. Immunohistochemistry was performed 
on free-floating sections (6–8 per mouse) as previously described (40) 
and stained for the AZIN2 viral HA tag (Roche, 12158167001), total 
human tau (HT7; Thermo Fisher Scientific, MN1000B), PHF (AT8, 
Thermo Fisher Scientific, MN1020B), and microglial activation (IBA1; 
Wako Chemicals USA, Inc., 016-26461).
Polyamine quantification. Polyamine quantification in brain 
homogenates was performed in collaboration with Sanford Burn-
ham Prebys. Total brain homogenates were subjected to liquid chro-
seconds the door opened to the dark chamber. Latency to cross 
into the dark chamber was characterized as basal inhibition (day 
1) and fear-associated recall (day 2). On day 1, increased latency 
indicated increased inhibition. On day 2, decreased latency indi-
cated impaired fear-associated recall. On both days, the maximum 
latency to cross was 300 seconds or 5 minutes.
Immunohistochemistry and staining. After completing the behavior-
al testing battery, mice were euthanized with SomnaSol and transcar-
dially perfused with 0.9% saline at 9 months of age. One hemisphere 
of the brain was dissected, frozen, and stored at –80°C for biochemical 
analysis; the opposite hemisphere was fixed in 4% paraformaldehyde 
in 100 mM phosphate buffer (pH 7.4) for 24 hours. Tissue was cryopro-
Figure 16. Polyamines decrease tau seeding while acetylpolyamines increase tau seeding. (A and B) Validation of tau seeding aggregation assay using 
TauRD P301S FRET biosensor cells by 10 nM active human recombinant tau441 (2N4R), P301S mutant tau preformed fibrils (Tau [P301S] PFFs), P = 0.000. 
Lipofectamine 2000 + 10 nM Tau PFFs increased seeding compared with no treatment and Lipofectamine 2000 alone (P = 0.000, P = 0.000, respectively) 
(C and D) There was a significant effect of treatment on tau aggregation as measured by percentage fluorescence (P = 0.000). Spermidine (300 μM) + 10 
nM Tau (P301S) PFFs decreased tau aggregation (P = 0.021), while acetylspermidine (300 μM) + 10 nM Tau (P301S) PFFs increased tau aggregation (P = 
0.008) compared with 10 nM Tau (P301S) PFFs alone. (E and F) There was a significant effect of treatment on tau aggregation as measured by percent-
age fluorescence (P = 0.000). Acetylspermine (300 μM) increased tau aggregation (P = 0.003). One-way ANOVA followed by post-hoc comparisons using 
Tukey’s HSD, n = 5, data represented by box-and-whisker plot displaying the minimum, first quartile, median, third quartile, and maximum; *P < 0.05.
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93482) on ice. Tissues were homogenized in 
20% (w/v) consisting of the buffer mentioned 
above, and an aliquot was centrifuged at 14,000g 
for 10 minutes at 4°C. The supernatant (S1) was 
transferred to another tube and subjected to 
BCA assay protein quantification. Approximate-
ly 20 μg of protein was resolved using 4%–20% 
gradient gel, transferred to PVDF, and probed 
for Tau5 (MilliporeSigma, MAB361), PHF Tau 
(AT8; Thermo Fisher Scientific, MN1020), 
AZIN2/ADC (Abcam, ab157214), and GAPDH 
(Meridian, H86504 male). After 3 TBS washes 
in 0.05% Tween 20, appropriate secondary anti-
bodies (Southern Biotechnologies, goat anti-rab-
bit [4010-05], goat anti-mouse [1070-05]) were 
used and detected with chemiluminescence 
(Thermo Fisher Scientific, P32106). Images 
were taken using the Azure Series C600 digital 
imager. All samples were normalized to their 
respective actin or GAPDH, and then calculated 
for fold change.
For mouse brain samples, Western blot 
analysis was performed as previously described 
(40). Briefly, dissected hippocampal tissue was 
weighed and resuspended at 10% (w/v) in mod-
ified RIPA buffer (50 mM Tris pH 7.6, 140 mM 
NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% 
SDS) with a 1% (v/v) protease inhibitor cocktail 
(Sigma-Aldrich, P8340) and phosphatase inhib-
itor cocktails 2 and 3 (Sigma-Aldrich, P5726 and 
P0044). Tissue was homogenized with a tissue 
homogenizer and centrifuged at 40,000g for 30 
minutes at 4°C. The supernatant containing the 
detergent-soluble fraction (S1) was analyzed by 
Western blot. The pellet (P1) containing the insol-
uble material was resuspended in 70% formic acid 
(20% volume of RIPA buffer used for homogeni-
zation) and incubated for 1 hour at room tempera-
ture. Formic acid was buffered with 1 M Tris, pH 
7.5 (3 times the volume of 70% formic acid used 
for pellet resuspension), and pH was adjusted 
with NaOH solution (50% w/w) added to a final 
pH of 7.5. Protein concentration was determined 
with the Pierce BCA protein assay (Thermo Fish-
er Scientific, P123225). Five micrograms of total 
protein (for S1 and P1) were loaded to measure 
tau epitopes, including tau total (H150; Santa Cruz Biotechnology, 
sc-5587), tau AT8 (Thermo Fisher Scientific, MN1020), tau pSer396 
(AnaSpec, 54977-025), and tau pSer199/202 (AnaSpec, 54963-025). 
Five to 10 micrograms of total protein were loaded to measure poly-
amine enzymes: AZIN2 (Abcam, ab157214), ODC (Epitomics/Abcam, 
S2610), SRM (Proteintech Group, 19858-1-AP), SMS (Epitomics/
Abcam, ab156879), SMOX (Proteintech Group, 15052-1-AP), SSAT 
(Abcam, ab105220), and PAOX (Proteintech Group, 189721-1-AP). 
The primary antibodies used for the cosedimentation assay Western 
blot analyses were β-tubulin 9F3 (Cell Signaling Technology, 2128) 
and total tau (H150; Santa Cruz Biotechnology, sc-5587).
matography with tandem mass spectrometry (LC-MS/MS) using a 
standard curve of polyamine analytes. Metabolites not quantified, 
such as acetylputrescine and acetylspermine, fell below the quanti-
tation limit and are therefore not reported.
Biochemical analysis, Western blotting, and dot blot. For human 
brain samples, frozen tissue (10–20 mg) was weighed in 1.5 mL tubes 
and submerged in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% 
NP-40, 0.1% SDS, 0.5% sodium deoxycholate, pH 7.4) with protease 
inhibitor cocktail (Sigma-Aldrich, P8340-5ML), phosphatase inhib-
itor cocktail 2 (Sigma-Aldrich, P5726-5ML), phosphatase inhibitor 
cocktail 3 (Sigma-Aldrich, P0044-5ML), and PMSF (Sigma-Aldrich, 
Figure 17. Hypothesized interactions of polyamines, tubulin, and tau. (A) Polyamines increase 
tubulin polymerization while also inhibiting tau aggregation. (B) Acetylpolyamines fail to increase 
and even reduce tubulin polymerization and promote tau fibrillization and aggregation. (C) In 
tauopathies, increased levels of polyamines facilitate tubulin polymerization but displace tau, 
leaving it vulnerable for aggregation by increased levels of acetylpolyamines.
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Tubulin polymerization assay. Tubulin assay was conducted 
using the manufacturer’s protocol (Cytoskeleton, Inc., BK006P) 
with slight modifications. Treatments consisted of polyamines 
(putrescine, spermidine, spermine, acetylputrescine, acetylsper-
mine) (Sigma-Aldrich, P5780, S4139, S4264, A8784, and O1467), 
N1-acetylspermidine spermine (Cayman Chemical, 9001535). 
Treatments were added to a 96-well plate, which was positioned on 
top of an ice bath before adding tubulin. Tubulin was reconstitut-
ed and placed on ice for 2 minutes, and then added to the tubulin 
reaction mix. The tubulin reaction mix was then added to each well 
using a multichannel pipette. The plate was loaded into a BioTek 
Synergy H1 plate reader for 24-, 48-, 72-, 98-, and 120-minute read-
ings at 37°C. Each compound was assessed in triplicate wells with 3 
independent tubulin preparations.
Tau-mediated tubulin morphology. Live-cell microscopy of 
HEK293T (ATCC, CRL-11268) cells coexpressing GFP-tubulin was 
performed as described previously (41) with slight modifications. 
Briefly, cells were transfected with GFP-tubulin constructs, and then 
4 hours later treated with vehicle or 0.5 mM or 1 mM spermine for 
48 hours. A minimum of 15–20 cells/condition were imaged live in 
phenol red–free complete medium using an Olympus FV1000 MPE 
multiphoton laser scanning microscope. Confocal Z-stack images (1 
μm slices) were captured using a ×10 or ×60 objective. Images were 
processed for tubulin morphology as described previously (41).
Cosedimentation assay. C3tau HeLa cells were cultured using OPTI-
MEM media containing 10% FBS, 100 units/mL penicillin, 100 μg/mL 
streptomycin, amphotericin B, and 0.3 μg/mL G-418. The cells were 
grown to 100% confluence and then washed with microtubule-stabiliz-
ing buffer (MSB) (85 mM Pipes, pH 6.93, 1 mM EGTA, 1 mM MgCl2, 2 M 
glycerol), which was kept at 37°C before adding to cells. Fresh MSB was 
For dot blot analysis, 30 μg of total protein from whole-cell 
homogenates was spotted onto wet nitrocellulose membrane and 
allowed to air dry. Membranes were washed with TBST (20 mM Tris, 
0.8% NaCl, pH 7.4, with 0.07% Tween 20), blocked with Blotto in TBS 
(Thermo Fisher Scientific, 137530) for 30 minutes, washed 3 times for 
10 minutes in TBST, and allowed to incubate with the primary anti-
tau oligomeric antibody (T22; MilliporeSigma, ABN454-1) overnight 
at 4°C, followed by three 10-minute washes. An HRP-conjugated sec-
ondary antibody (Southern Biotechnologies goat anti-rabbit, 4010-
05) was allowed to incubate for 2 hours. Then the membranes were 
washed 3 times for 10 minutes in TBST and developed using Pierce 
ECL Western blotting substrate (P32106) and LabScientific Autorad 
blue film to detect the chemiluminescence signal.
Treatment of C3tau HeLa cells with polyamines. C3tau HeLa 
(C3H/tau) cells stably overexpressing human WT 4R0N tau were 
cultured in 100-mm dishes using OPTIMEM media containing 
10% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, 
amphotericin B, and 0.3 μg/mL G-418. Cells were grown to 90% 
confluence and treated with putrescine, spermidine, and spermine 
(0–1 mM) (Sigma-Aldrich, P5780, S4139, and S4264) for 72 hours 
in the presence of 1 mM aminoguanidine (Sigma-Aldrich, 396494). 
For specific experiments, cells were treated for 24 hours under the 
same conditions. Cells were washed in PBS and harvested for West-
ern blot analysis.
Cells were washed in PBS, collected, and lysed with modified 
RIPA buffer (as above). Next, cells were centrifuged at 14,000g for 
15 minutes at 4°C and the soluble protein lysate was collected and 
quantified by BCA protein assay. Approximately 15 μg of protein was 
resolved using 4%–20% gradient gel, transferred to PVDF, and probed 
for tau and SSAT (as described above) by Western blot analysis.
Figure 18. Hypothesized model and mechanism of findings. Our 
working model is that AZIN2 overexpression induces a unique poly-
amine stress response, characterized by increases in putrescine, sper-
mine, and acetylspermidine. Although polyamines may possess acute 
stabilizing effects on tubulin polymerization and tau fibrillization, 
long-term accumulation may also contribute to disease progression 
through indirect mechanisms, such as tau displacement and accumu-
lation of acetylated byproducts, which creates a feed-forward cycle of 
disease progression, leading to cognitive and affective impairments.
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for an additional 48 hours with polyamines and PFFs and imaged at 
×4 magnification using the Citation 3 Imager. Additional wells (n = 6 
wells) were harvested and collected from each treatment and subject-
ed to flow cytometry to measure fluorescence aggregates within cells. 
Experiments were replicated 3 independent times.
Statistics. All statistical analyses were performed using SPSS ver-
sion 25. Statistical outliers were defined as falling more than 2 stan-
dard deviations from the mean. Data are represented by mean ± SEM 
scatter with bar graphs or by box-and-whisker plot displaying the min-
imum, first quartile, median, third quartile, and maximum. The box 
represents the first to third quartile, the line in the middle of the box is 
the median, and the whiskers span from each quartile to the minimum 
or maximum. A P value less than 0.05 was considered significant.
A 1-way ANOVA followed by Tukey’s honestly significant differ-
ence (HSD) post hoc analyses was performed for Figures 2, 15, and 
16. A 1-way ANOVA followed by post hoc comparison using Dunnett’s 
2-sided correction was performed for Figures 11, 12, and 14. A 2 × 2 fac-
torial ANOVA followed by pairwise comparison using Sidak’s posttest 
correction was performed for Figures 3–9. AUC was calculated using 
GraphPad Prism, and data are represented as averages of triplicate 
wells for tubulin polymerization assays and ThT assays.
For human AD Western blot analyses, n = 2 unaffected control was 
removed because of Braak Stage 3 categorization and as a statistical 
outlier, and n = 1 (AD/AT8+) was removed from Tau5 and AZIN2 analy-
ses as a statistical outlier. The remaining numbers of samples (n) were 
the following: Tau 5 (40–64 kDa) unaffected control n = 9 (4 male, 5 
female) (AD/AT8+) n = 9 (3 male, 6 female), (AD/AT8–) n = 5 (4 male, 
1 female); Tau5 (100–140 kDa) unaffected control n = 9 (4 male, 5 
female), (AD/AT8+) n = 9 (4 male, 5 female), (AD/AT8–) n = 5 (4 male, 1 
female); (AT8) unaffected controls n = 9 (4 male, 5 female), (AD/AT8+) 
n = 10 (4 male, 6 female), (AD/AT8–) n = 5 (4 male, 1 female); AZIN2 
controls n = 9 (4 male, 5 female), (AD/AT8+) n = 9 (4 male, 5 female), 
(AD/AT8–) n = 5 (4 male, 1 female).
A total of n = 3 (1 male, 2 female) from nTg AAV9-AZIN2 group 
and n = 2 (2 female) from PS19 AAV9-AZIN2 group viral expression 
outliers were removed from behavioral analyses and polyamine quan-
tification for insufficient cortical viral expression. For the HA stain and 
behavioral testing, after the removal of viral outliers, group sizes were 
as follows: nTg AAV9-EC n = 11 (7 male, 4 female); nTg AAV9-AZIN2: 
n = 6 (5 male, 1 female); PS19-AAV9 EC: n = 12 (6 male, 6 female); PS19 
AAV9-AZIN2: n = 9 (7 male, 2 female). Additionally, n = 1 (female) 
mouse from the PS19 AAV9-AZIN2 group did not complete behavioral 
testing because of hind-limb paralysis; therefore, the group size for Y 
maze and inhibitory avoidance testing was n = 8. For the HT7, AT8, and 
IBA1 stains, group sizes were nTg AAV9-EC: n = 7 (4 male, 3 female); 
nTg AAV9-AZIN2: n = 3 (2 male, 1 female); PS19 AAV9-EC: n = 7 (2 
male, 5 female); PS19 AAV9-AZIN2: n = 8 (7 male, 1 female). For poly-
amine quantification, group sizes were: nTg AAV9-EC: n = 8 (4 male, 
4 female); nTg AAV9-AZIN2: n = 5 (5 male); PS19 AAV9-EC: n = 8 (5 
male, 3 female); PS19 AAV9-AZIN2: n = 6 (4 male, 2 female). A total of 
n = 3 (2 male, 1 female) samples fell beyond the upper limit of quanti-
fication for putrescine and were removed from the PS19 AAV9-AZIN2 
group. For hippocampal Western blot analyses, distributions were nTg 
AAV9-EC: n = 6 (4 male, 2 female); nTg AAV9-AZIN2: n = 6 (4 male, 2 
female); PS19 AAV9-EC: n = 6 (4 male, 2 female); PS19 AAV9-AZIN2: 
n = 6 (3 male, 3 female). For hippocampal dot-blot analyses, group dis-
tributions were nTg AAV9-EC: n = 8 (5 male, 3 female); nTg AAV9-AZ-
then added to the dish while cells were removed, using a cell scraper 
at 37°C and a thermo-bead heating bath. Cells were removed, and then 
centrifuged at 450g for 10 minutes to remove the buffer. The cell pellet 
was then lysed using polymerizing buffer (40 mM MES-KOH, pH 6.9, 
1 mM GTP, 1 mM DTT, 4 mM MgCl2; 1% protease inhibitor, Sigma-Al-
drich, P8340-5ML; 1% PMSF, Sigma-Aldrich, 93482; 1% phosphatase 
inhibitor cocktail 2, Sigma-Aldrich, P5726-1ML; 1% phosphatase inhib-
itor cocktail 3, Sigma-Aldrich, P0044-1ML; MES-KOH) with 0.4% Tri-
ton X-100, which was kept at 37°C. Cells were sonicated with 5 pulses 
and homogenates were centrifuged at 25,000g for 15 minutes at 37°C. 
The supernatant was removed and stored in a 1.5 mL Eppendorf tube. 
The pellets were resuspended in MES-KOH, incubated for 10 minutes 
at 4°C, placed on ice, and separated into 4 tubes, which consisted of 4 
groups: control, 0.5 mM spermine, 1 mM spermine, and 3 mM sper-
mine. The samples were incubated for 30 minutes with the appropriate 
polyamine at 37°C, and then centrifuged at 25,000g for 15 minutes. The 
supernatant was removed for Western blot analyses. The heavy pellet 
was resolubilized in 30 μL of MES-KOH and analyzed by Western blot. 
A graphical representation of the assay is in Supplemental Figure 1.
ThT assay. Recombinant 4R0N WT tau was purified as described 
previously (42). For the ThT assay, 30 μM tau was combined with 10 
μM ThT (Sigma-Aldrich) in 10 mM sodium phosphate, pH 7.4 buffer. 
Putrescine, spermidine, spermine, acetylputrescine, acetylspermine, 
N1-acetylspermidine spermine, or vehicle control were added to black, 
clear-bottom 96-well plates. Aggregation was initiated with 4 μM hep-
arin, less than 2% of total well volume, and samples were incubated in 
a BioTek Synergy H1 plate reader for 0–24 hours and read at excitation 
wavelength 444 nm and emission wavelength 482 nm. Each compound 
was assessed in triplicate wells with 3 independent tau preparations.
Split GFP-tau oligomerization assay. N2a-ssGT cells described previ-
ously (24) were used for oligomerization assays. Cells were cultured using 
DMEM (Gibco, 31053028) as basal medium and supplemented with 
10% FBS, 1% (v/v) GlutaMAX (2 mM), penicillin (100 IU/mL), strepto-
mycin (100 μg/mL), and sodium pyruvate (1 mM). Cells were maintained 
at 37°C in a 5% CO2 humidified incubator. Cells were plated evenly on 
Costar clear-bottom, black-side 96-well plates (3603, Corning) at 10,000 
per well. On the following day, cells were treated with putrescine dihydro-
chloride, N-acetylputrescine hydrochloride, spermidine, N1-acetylsper-
midine hydrochloride, spermine, N1-acetylspermine trihydrochloride 
(Sigma-Aldrich) at a final concentration of 30 μM supplemented with 1 
mM aminoguanidine hydrochloride (Sigma-Aldrich) to inhibit bovine 
amine oxidase. After 72 hours of treatment, cells were read and imaged 
for GFP fluorescence using a BioTek Cytation 3 reader, and then imme-
diately harvested as a single-cell suspension medium for detecting GFP 
percentage by an Accuri C6 flow cytometer (BD Biosciences).
Polyamine treatment in biosensor cells. Tau RD P301S FRET biosen-
sor cells (ATCC, CRL-3275) were cultured in DMEM media contain-
ing 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin. 
Tau RD biosensor cells were grown to 90% confluence and reseeded 
in 96-well clear-bottom plates. Spermidine, spermine, acetylsper-
midine, and acetylspermine (0–300 μM) along with 1 mM amino-
guanidine (Sigma-Aldrich) were added to Tau RD biosensor cells in 
serum-free media for 2 hours. Ten nanomolar (final concentration) 
of active human recombinant tau441 (2N4R) P301S mutant tau (tau 
PFFs) (StressMarq, SPR-329) complexed with Lipofectamine 2000 
(1:2.5 PFF/Lipofectamine 2000) in serum-free media was added for 
an additional 2 hours. Tau RD biosensor cells were allowed to incubate 
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